A clinical trial, coordinated by Matthieu Jabaudon, PU-PH within the Translational Approach to Epithelial Lesions and Their Repair team, provides essential data on sedation strategies in intensive care. These groundbreaking results have been published in the prestigious journal JAMA, where they are the subject of an editorial. Additionally, they were presented during the inaugural session of the 44th International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels.

This clinical trial, SESAR (Sevoflurane for Sedation in Acute Respiratory Distress Syndrome), sponsored by the Clermont-Ferrand University Hospital, evaluated the efficacy and safety of inhaled sevoflurane compared to intravenous propofol for sedation in adult intensive care patients with moderate to severe acute respiratory distress syndrome (ARDS). Conducted across 37 intensive care units in France, this trial included 687 patients. Its results indicate that sevoflurane sedation is associated with a reduction in the number of ventilator-free days at 28 days and lower 90-day survival compared to intravenous propofol sedation. These findings will help guide clinical practices and future recommendations for the management of patients with ARDS.

To learn more:

link to article : jama_jabaudon_2025_oi_250013_1742222882.40904  (Jabaudon et al., JAMA. 2025 Mar 18.doi: 10.1001/jama.2025.3169).

linl to editorial : jama_venkatesh_2025_ed_250013_1742222891.41076